A research group led by Associate Professor Tetsuya Muramoto from the Faculty of Science, Toho University, has established a CRISPR genome editing technique that enables comparative analysis of the ...

CRISPR gene drives bias inheritance in pests, advancing population-level control while raising questions about resistance and ...

UC San Diego researchers have created a new system that reveals specific categories of potentially risky mutations resulting from CRISPR edits. This high magnification image reveals CRISPR-based DNA ...

Researchers at Vilnius University (Lithuania) have uncovered how the bacterial protein Cas9, better known as the CRISPR-Cas ...

The FDA has issued draft guidance that could speed up approval pathways for rare disease therapies using genome editing technologies. This framework is directly relevant to CRISPR Therapeutics, which ...

A Swiss biotechnology company said it has used the gene-editing technology CRISPR to treat a patient with a dangerous blood disease called beta thalassemia, marking the technology’s first trial run by ...

CRISPR Therapeutics (NasdaqGM:CRSP) reports material progress in commercializing Casgevy, the first FDA approved gene editing therapy for sickle cell disease. Reimbursement and access for Casgevy now ...

If you are wondering whether CRISPR Therapeutics at around US$53.52 is offering good value today, you are not alone. The stock often attracts investors who care about price versus potential. The share ...

Crispr Therapeutics (CRSP) is downgraded to "Hold" as current valuation already reflects optimism for CTX310 Phase I results and pipeline progress. Intellia Therapeutics (NTLA) maintains a "Buy" ...